1642581-63-2

Usage

Uses

Used in Pharmaceutical Industry:
SCC-244 is used as an anticancer agent for targeting c-Met kinase, which plays a crucial role in tumor growth and progression. Its high selectivity and potency make it an effective treatment option for various types of cancer, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC).
Additionally, SCC-244 can be used in combination with other targeted therapies or chemotherapy to enhance the overall treatment efficacy and overcome potential resistance mechanisms in cancer cells. Its ability to induce tumor regression in preclinical models highlights its potential as a valuable addition to the arsenal of cancer therapeutics.

References

Ai et al. (2018), Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models; Cancer Res., 17 751

Upstream product

• 761446-44-0 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 6188-23-4 6-bromoimidazo[1,2-a]pyridine 
• 1150617-54-1 6-bromo-1H-pyrazolo[4,3-b]pyridine 

Relevant academic research and scientific papers

Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b ]pyridines as selective c-met inhibitors

c-Met has emerged as an attractive target for targeted cancer therapy because of its abnormal activation in many cancer cells. To identify high potent and selective c-Met inhibitors, we started with profiling the potency and in vitro metabolic stability of a reported hit 7. By rational design, a novel sulfonylpyrazolo[4,3-b]pyridine 9 with improved DMPK properties was discovered. Further elaboration of π-π stacking interactions and solvent accessible polar moieties led to a series of highly potent and selective type I c-Met inhibitors. On the basis of in vitro and in vivo pharmacological and pharmacokinetics studies, compound 46 was selected as a preclinical candidate for further anticancer drug development.

FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumours associated with abnormal protein tyrosine kinase.